11 completed, 3 terminated, 1 unknown. 5 Phase 1, 4 Phase 2, 2 Phase 3, 1 Early Phase 1, 1 Not applicable.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 5 | Completed 5 |
| Phase 2 | 4 | Completed 3, Terminated 1 |
| Phase 3 | 2 | Completed 1, Unknown 1 |
| Early Phase 1 | 1 | Completed 1 |
| Not applicable | 1 | Terminated 1 |
Follow Undifferentiated Ovarian Carcinoma: new trials by email Literature Review of Undifferentiated Ovarian Carcinoma trials Research Report on Undifferentiated Ovarian Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Pembrolizumab, Bevacizumab, and Cyclophosphamide in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Bevacizumab, Cyclophosphamide, Laboratory Biomarker Analysis - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 2 | Completed | Roswell Park Cancer Institute | 40 | 2016-09-01 | 2021-10-06 |
| Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer Everolimus, Laboratory Biomarker Analysis, Letrozole - Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma | Phase 2 | Completed | Mayo Clinic | 20 | 2014-11-14 | 2020-10-23 |
| Vaccine Therapy for Patients With Stage IIIC-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cavity Cancer Laboratory Biomarker Analysis, Multi-epitope Folate Receptor Alpha-loaded Dendritic Cell Vaccine - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Tumor | Early Phase 1 | Completed | Mayo Clinic | 19 | 2014-04-14 | 2025-10-31 |
| Diet and Physical Activity Change or Usual Care in Improving Progression-Free Survival in Patients With Previously Treated Stage II, III, or IV Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Behavioral Dietary Intervention, Compliance Monitoring, Counseling - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Unknown | Gynecologic Oncology Group | 1070 | 2012-06-18 | 2018-02-19 |
| Pegylated Liposomal Doxorubicin Hydrochloride, Carboplatin, Veliparib, and Bevacizumab in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer Bevacizumab, Carboplatin, Laboratory Biomarker Analysis - Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 41 | 2011-10-11 | 2019-07-22 |
| Granisetron, Aprepitant, and Dexamethasone in Preventing Nausea and Vomiting in Patients Receiving Chemotherapy for Stage II, III, or IV Ovarian Cancer Adjuvant Therapy, Aprepitant, Carboplatin - Nausea and Vomiting, Ovarian Brenner Tumor | Not applicable | Terminated | Gynecologic Oncology Group | 4 | 2011-06-01 | 2018-05-22 |
| TLR8 Agonist VTX-2337 and Pegylated Liposomal Doxorubicin Hydrochloride or Paclitaxel in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer TLR8 Agonist VTX-2337, Diagnostic Laboratory Biomarker Analysis, Pharmacological Study - Malignant Ovarian Mixed Epithelial Tumor, Ovarian Brenner Tumor | Phase 1 | Completed | Gynecologic Oncology Group | 20 | 2011-03-01 | 2014-12-25 |
| Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Bortezomib, Carboplatin, Laboratory Biomarker Analysis - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 1 | Completed | National Cancer Institute (NCI) | 33 | 2010-04-05 | 2019-08-09 |
| Changes in Brain Function in Patients With Stage I, Stage II, Stage III, or Stage IV Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Are Receiving Chemotherapy Cognitive Assessment, Quality-of-Life Assessment - Cognitive Side Effects of Cancer Therapy, Malignant Ovarian Epithelial Tumor | Completed | Gynecologic Oncology Group | 247 | 2010-04-01 | 2018-04-12 | |
| A6 in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Urokinase-Derived Peptide A6, Laboratory Biomarker Analysis - Fallopian Tube Carcinoma, Malignant Ovarian Mixed Epithelial Tumor | Phase 2 | Completed | Gynecologic Oncology Group | 31 | 2009-07-01 | 2019-01-15 |
| Cisplatin and Paclitaxel in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cavity Cancer Paclitaxel, Cisplatin - Chemotherapeutic Agent Toxicity, Endometrial Adenocarcinoma | Phase 1 | Completed | Gynecologic Oncology Group | 23 | 2009-02-01 | 2014-12-31 |
| YKL-40 in Serum Samples From Patients With Newly Diagnosed Stage III-IV Ovarian Epithelial, Primary Peritoneal Cavity, or Fallopian Tube Cancer Receiving Chemotherapy Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis - Fallopian Tube Adenocarcinoma, Fallopian Tube Clear Cell Adenocarcinoma | Terminated | Gynecologic Oncology Group | 2500 | 2007-09-01 | 2018-05-22 | |
| Carboplatin and Paclitaxel With or Without Bevacizumab in Treating Patients With Stage III or Stage IV Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer Bevacizumab, Carboplatin, Laboratory Biomarker Analysis - Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma | Phase 3 | Completed | National Cancer Institute (NCI) | 1873 | 2005-09-01 | 2019-07-23 |
| Polyglutamate Paclitaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Peritoneal, or Fallopian Tube Cancer Carboplatin, Paclitaxel Poliglumex, Pharmacological Study - Fallopian Tube Carcinoma, Malignant Ovarian Mixed Epithelial Tumor | Phase 1 | Completed | Gynecologic Oncology Group | 32 | 2003-04-01 | 2015-05-08 |
| Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Stage III Ovarian Cancer Carboplatin, Cyclophosphamide, Filgrastim - Malignant Ovarian Mixed Epithelial Tumor, Ovarian Clear Cell Cystadenocarcinoma | Phase 2 | Terminated | Gynecologic Oncology Group | 12 | 1999-11-01 | 2017-08-09 |
Fallopian Tube Neoplasms (14) · Ovarian Neoplasms (14) · Brenner Tumor (10) · Dysgerminoma (1) · Nausea (1) · Neurotoxicity Syndromes (1) · Teratoma, Ovarian (1) · Vomiting (1)
Adnexal Diseases (15) · Endocrine System Diseases (15) · Female Urogenital Diseases (15) · Female Urogenital Diseases and Pregnancy Complications (15) · Genital Diseases (15) · Genital Diseases, Female (15) · Genital Neoplasms, Female (15) · Gonadal Disorders (15) · Neoplasms (15) · Neoplasms by Site (15) · Ovarian Diseases (15) · Urogenital Diseases (15) · Urogenital Neoplasms (15) · Endocrine Gland Neoplasms (14) · Fallopian Tube Diseases (14)
Carboplatin (6) · Paclitaxel (4) · Taxes (4) · Bevacizumab (3) · Disulfides (3) · Immunoglobulin G (3) · Cisplatin (2) · Cyclophosphamide (2) · 1,2-diaminocyclohexaneplatinum II citrate (1) · Aprepitant (1) · Bortezomib (1) · Calcium Dobesilate (1) · Chemotherapy, Adjuvant (1) · Counseling (1) · Dexamethasone (1)
Gynecologic Oncology Group (9) · National Cancer Institute (NCI) (3) · Mayo Clinic (2) · Roswell Park Cancer Institute (1)
United States (15) · Canada (1) · Japan (1) · South Korea (1)
Don Dizon (2) · Bradley Monk (1) · David Alberts (1) · Emese Zsiros (1) · Gerardo Colon-Otero (1) · Katherine Bell-McGuinn (1) · Lisa Hess (1) · Lisa Landrum (1) · Mark Morgan (1) · Matthew S. Block, M.D., Ph.D. (1) · Michael Gold (1) · Robert Burger (1) · Russell Schilder (1) · Steven Plaxe (1)
PMID 21941283, PMID 22204724, PMID 23219660, PMID 26487588, PMID 27394382, PMID 28341300, PMID 29550184, PMID 31216226, PMID 33211063, PMID 35144591, PMID 36252167, PMID 36608382, PMID 37185961, PMID 39638782
U10CA027469 (9), U10CA180868 (4), U10CA101165 (3), P30CA015083 (1), P50CA136393 (1), U10CA180830 (1), UG1CA189867 (1)